TABLE 1

List of anti-claudin monoclonal antibodies and their applications

TargetNames of mAb ClonesIntended ApplicationMechanisms or SpecificationsReferences
CLDN-17A5DDSModulated epidermal barrierNakajima et al. (2015)
CLDN-1OM-7D3-B3HCVPrevented HCV entry into hepatocytes by inhibiting CLDN-1 and CD81 interaction.Fofana et al. (2010)
5.16Hötzel et al. (2011)
3A2Fukasawa et al. (2015)
D10XPaciello et al. (2016)
CLDN-13A2CancerKilled tumors through ADCCHashimoto et al. (2016b)
6F6Cherradi et al. (2017)
CLDN-21A2IBDEnhanced barrier strength of inflamed gastrointestinal barrierTakigawa et al. (2017)
CLDN-21A2CancerKilled tumor through ADCCHashimoto et al. (2018a)
CLDN-3KM3953CancerKilled tumor through ADCCAndo et al. (2015)
IgGH6Romani et al. (2015)
CLDN-4KM3934CancerKilled tumor through ADCC and enhanced penetration of antitumor drugs into tumor by modulating weak interaction between cancer cellsSuzuki et al. (2009)
4D3Kuwada et al. (2015)
5D12Hashimoto et al. (2016a)
Clone 382321Torres et al. (2018)
CLDN-4HKH-189Cell sortingSorted minor cell populations from thymocytes and enteroendocrine cellsKawai et al. (2011)
Nagatake et al. (2014)
CLDN-3 and -4KM3907CancerKilled tumor through ADCCKato-Nakano et al. (2010)
5A5Li et al. (2014a)
CLDN-5R9DDSEnhanced drug penetration into brain by modulating blood-brain barrierHashimoto et al. (2017b)
2B12Hashimoto et al. (2018b)
CLDN-6IMAB027CancerKilled tumor through ADCCMicke et al. (2014)
CLDN-6Clone 342927Cell sortingSorted residual pluripotent stem cells from differentiated cell populationsBen-David et al. (2013)
CLDN-6WU-9E1-G2HCVRevealed that these CLDNs could function as HCV entry receptors in nonhepatocyte cell lines but not in hepatocytesFofana et al. (2013)
CLDN-9YD-4E9-A2
CLDN-18.2IMAB362CancerKilled tumor through ADCCWöll et al. (2014)

  • ADCC, antibody-dependent cellular cytotoxicity; DDS, drug delivery system.